Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 6 No. 11, November 2005
Right arrow Erratum
Right arrow E-Letters: Submit a response
Right arrow E-Letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aranda, J. V.
Right arrow Articles by Thomas, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Aranda, J. V.
Right arrow Articles by Thomas, R.

NeoReviews Vol.6 No.11 2005 e516
© 2005 American Academy of Pediatrics

Pharmacology Review

Intravenous Ibuprofen for Preterm Newborns

J. V. Aranda, MD, PhD, FRCPC, FAAP*
Ronald Thomas, PhD*

* Pediatric Pharmacology Research Unit Network, Division of Clinical Pharmacology and Toxicology, Children’s Hospital of Michigan, Detroit, Mich

The first 300 words of the full text of this article appear below.


   Introduction
 
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is a chiral compound derived from arylproprionic acid. It is used widely as an antipyretic, anti-inflammatory, and analgesic agent and for therapy of arthritis. It was approved by the United States Food and Drug Administration in 1974 and later became available as an over-the-counter drug. In 1979, Cocceani and associates (1) demonstrated a dose-dependent constriction of the ductus arteriosus caused by ibuprofen in newborn lambs. Its current use in human newborns was stimulated by its demonstrated improvement of cerebral blood flow (CBF) autoregulation in newborn animals (2) and its potential to offer some degree of neuroprotection. In contrast to indomethacin, ibuprofen did not decrease and impair regional blood flow to the brain in newborn infants and animals. (3)

In addition to neuroprotection, ibuprofen also may close the patent ductus arteriosus (PDA) in newborn humans, as has been shown in newborn lambs. A pilot study published in 1996 suggested that, compared with placebo, intravenous (IV) ibuprofen closed the PDA and shortened the hospital stay in preterm newborns with minimal renal adverse effects. (4) The development of two IV formulations of ibuprofen (ibuprofen lysine and ibuprofen THAM) permitted evaluation of this drug in preterm newborns. To date, efficacy, safety, dose finding, pharmacokinetic, and pharmacodynamic data in the newborn indicate that this drug is effective for ductal closure in preterm neonates. Data on safety depend on the formulation studied. (5)(6) This review examines the published data on ibuprofen up to June 2005 and concludes that ibuprofen lysine is a safe and effective drug for PDA closure in newborns.


   Clinical Studies
 
More than 20 clinical trials have compared IV ibuprofen with placebo or indomethacin; others have evaluated the pharmacodynamic effects of the drug before and after its administration. . . . [Full Text of this Article]




E-Letters:

Read all E-Letters

Typographical error
Thomas E Young
Neoreviews Online, 17 Nov 2005 [Full text]

HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Academy of Pediatrics.